Pharmacokinetics of vancomycin and dosing recommendations for trauma patients

Medellín-Garibay, Susanna E.; Ortiz-Martín, Belén; Rueda-Naharro, Aída; García, Benito; Romano-Moreno, Silvia; Barcia, Emilia
February 2016
Journal of Antimicrobial Chemotherapy (JAC);Feb2016, Vol. 71 Issue 2, p471
Academic Journal
Objectives: The objectives of this study were to characterize the population pharmacokinetics of vancomycin in trauma patients and to propose dosing schemes to optimize therapy. Patients and methods: Trauma patients from Hospital Universitario Severo Ochoa (Spain) receiving intravenous vancomycin and routine therapeutic drug monitoring were included. Concentrations and time data were retrospectively collected, and population modelling was performed with NONMEM 7.2; internal and external validationswere performed to probe the final model. Finally, several simulationswere executed to propose dosing guidelines to reach expected vancomycin concentrations. Results: A total of 118 trauma patients were included; the population was 45% males, with a mean age of 77 years (range 37-100 years) and a mean total body weight (TBW) of 72 kg (range 38-110 kg). The pharmacokinetics of vancomycin was best described by a two-compartment open model; creatinine clearance (CLCR)was related to vancomycin clearance (0.49+0.04 L/h), being diminished by the presence of furosemide (0.34+0.05 L/h). TBWinfluenced both the central volume of distribution (V10.74+0.1 L/kg) and peripheral volume of distribution (V25.9+2 L/kg), but patients with age .65 years showed a larger V1 (1.07+0.1 L/kg). Bootstrapping was performed to internally validate the stability of the final model. External validation was developed using an alternate population of 40 patients with the same characteristics. The validated model was compared with population pharmacokinetic models previously published and showed better predictive performance for trauma patients than the current one. This final model allowed us to propose a newpractical dose guideline to reach higher trough concentrations (15-20 mg/L) and AUC0-24/MIC ratios of more than 400 after 4 days of vancomycin treatment. Conclusions: A new population model was described for trauma patients to optimize vancomycin therapy, showing precise predictive performance to be applied for therapeutic drug monitoring and providing a new practical dose guideline that considers CLCR and concomitant administration of furosemide for these patients.


Related Articles

  • Psychometric Characteristics of the Brief Wisconsin Inventory of Smoking Dependence Motives Among a Nonclinical Sample of Smokers. Adkison M. A., Sarah E.; Rees, Vaughan W.; Travers, Maansi Bansal-Travers; Hatsukami, Dorothy K.; O'Connor, Richard J.; Adkison, Sarah E; Bansal-Travers, Maansi // Nicotine & Tobacco Research;Apr2016, Vol. 18 Issue 4, p470 

    Introduction: Attempts to validate the Brief Wisconsin Inventory of Smoking Dependence Motives (WISDM) have produced mixed results. The objectives for the current research were to (1) evaluate the test-retest reliability, internal consistency, and concurrent validity for each of the...

  • Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. Ryuichi Hirano; Yuichi Sakamoto; Junichi Kitazawa; Shoji Yamamoto; Naoki Tachibana // Infection & Drug Resistance;Oct2016, Vol. 9, p243 

    Background: Vancomycin (VCM) requires dose adjustment based on therapeutic drug monitoring. At Aomori Prefectural Central Hospital, physicians carried out VCM therapeutic drug monitoring based on their experience, because pharmacists did not participate in the dose adjustment. We evaluated the...

  • Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Tod, M.M.; Padoin, C.; Petitjean, O. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 11, p803 

    Measurements of aminoglycoside concentration in serum are used to individualise dosage regimens (dose per administration and/or administration interval) with the goal of attaining the desired therapeutic range as quickly as possible. Therapeutic range is defined in terms of peak concentration...

  • Rate and Extent of Drug Accumulation after Multiple Dosing Revisited. Brocks, Dion R.; Mehvar, Reza // Clinical Pharmacokinetics;2010, Vol. 49 Issue 7, p421 

    For drugs that have a narrow therapeutic margin in their concentration-effect profile, blood concentration measurements can be an invaluable guide to the individualization of dosage regimens. For clinicians involved in therapeutic drug monitoring, background knowledge of basic pharmacokinetics...

  • Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Bartelink, Imke H.; Rademaker, Carin M. A.; Schobben, Alfred F. A. M.; van den Anker, John N. // Clinical Pharmacokinetics;2006, Vol. 45 Issue 11, p1077 

    The approach to paediatric drug dosing needs to be based on the physiological characteristics of the child and the pharmacokinetic parameters of the drug. This review summarises the current knowledge on developmental changes in absorption, distribution, metabolism and excretion and combines...

  • Vancomycin Dosing in Neutropenic Patients. Haeseker, Michiel B.; Croes, Sander; Neef, Cees; Bruggeman, Cathrien A.; Stolk, Leo M. L.; Verbon, Annelies // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Background: To compare vancomycin pharmacokinetic parameters in patients with and without neutropenia. Methods: Patients ≥18 years admitted on general wards were included. Routinely vancomycin trough and peak plasma concentrations were measured with a fluorescence polarization...

  • Acute-phase Response Alters the Disposition Kinetics of Cefepime following Intravenous Administration to Rabbits. A. Goudah; S. Mouneir; Y. Sunwoo; J. Jang; J. Shin; J. Shim; M. Shimoda // Veterinary Research Communications;Jan2007, Vol. 31 Issue 1, p67 

    Abstract??The effect of experimentally induced fever on the pharmacokinetics of cefepime administered intravenously at a dose of 75 mg/kg bw was studied in six healthy rabbits. The study was conducted in two consecutive phases, separated by a washout period of 2 weeks. Infection was induced by...

  • Diuretic Strategies in Persons with Acute Decompensated Heart Failure. Moon, Kenneth T. // American Family Physician;5/1/2012, Vol. 85 Issue 9, Special section p1 

    The article focuses on a study which initiated the Diuretic Optimization Strategies Evaluation trial to assess different diuretic schemes for acute decompensated heart failure. Patients are said to receive intravenous furosemide arbitrarily which had two interventions including low as opposed to...

  • Therapeutic Drug Monitoring in Clinical Research. Neef, Cees; Touw, Daniel J.; Stolk, Leo M. // Pharmaceutical Medicine - New Zealand;2008, Vol. 22 Issue 4, p235 

    The development of a new drug is characterized by distinct developmental stages, usually described as phases I to IV. Dose tolerance and dose response exploration studies are undertaken in phase II or III. Pharmacokinetic studies are often involved in these phases, but frequently only as an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics